Acute angle closure glaucoma induced by selective serotonin reuptake inhibitor, and reversed by agomelatine

Karaytug M. O., Tamam L., DEMİRKOL M. E.

CUKUROVA MEDICAL JOURNAL, vol.44, no.4, pp.1520-1523, 2019 (ESCI) identifier

  • Publication Type: Article / Article
  • Volume: 44 Issue: 4
  • Publication Date: 2019
  • Doi Number: 10.17826/cumj.572186
  • Journal Name: CUKUROVA MEDICAL JOURNAL
  • Journal Indexes: Emerging Sources Citation Index (ESCI), TR DİZİN (ULAKBİM)
  • Page Numbers: pp.1520-1523
  • Çukurova University Affiliated: Yes

Abstract

Agomelatine, a MT1 (Melatonin) and MT2 receptor agonist and 5-HT2C (5-Hidroksitriptamin) antagonist, is an antidepressant agent used in the treatment of major depressive disorders. Intraocular pressure lowering effect of melatonin and its analogues have been demonstrated in a few experimental studies. In the present case report, we have documented the reversal of angle closure glaucoma by oral agomelatine in a patient with major depressive disorder under selective serotonine reuptake inhibitor treatment. The patient, who had previously been diagnosed with glaucoma, was also receiving antiglaucomatous treatment.